论文部分内容阅读
目的探讨并分析在晚期消化道肿瘤患者中DC-CIK细胞免疫治疗联合化疗的临床效果。方法选取山东省临沂市平邑县中医院消化内科2011年10月至2013年11月收治的40例无手术适应证的晚期消化道肿瘤患者,采用随机分组的方式,将患者分成观察组(标准化疗方案+DC-CIK细胞免疫治疗)和对照组(单纯标准化疗方案),对比两组近期疗效、安全性、生活质量、1年期生存率。结果观察组有效率和疾病控制率分别为80%和50%,对照组有效率和疾病控制率分别为75%和50%,两组患者近期疗效差异无统计学意义(P>0.05)。观察组肿瘤标志物下降率、Karnofsky评分改善率、免疫功能改善及1年期生存率均高于对照组(P<0.05)。在骨髓抑制程度及胃肠道反应方面,两组比较差异亦无统计学意义(P>0.05)。结论在晚期消化道肿瘤的治疗中,DC-CIK细胞免疫治疗联合标准化疗方案,不能提高晚期消化道肿瘤患者的短期疗效,但可以提高患者生存质量及1年期生存率,且安全性好,无明显毒副反应。
Objective To investigate and analyze the clinical effects of DC-CIK cellular immunotherapy combined with chemotherapy in patients with advanced gastrointestinal cancer. Methods Forty patients with advanced gastrointestinal cancer without operation indications admitted from January 2011 to November 2013 in Department of Gastroenterology, Pingyi Hospital of Traditional Chinese Medicine, Linyi, Shandong Province were randomly divided into observation group (standard Chemotherapy + DC-CIK cell immunotherapy) and control group (standard chemotherapy alone), compared two groups of short-term efficacy, safety, quality of life, 1-year survival rate. Results The effective rate and disease control rate were 80% and 50% respectively in the observation group and 75% and 50% in the control group and the disease control group respectively. There was no significant difference in the short term efficacy between the two groups (P> 0.05). The observation group tumor marker decline rate, Karnofsky score improvement rate, improved immune function and 1-year survival rate were higher than the control group (P <0.05). In the degree of bone marrow suppression and gastrointestinal reactions, there was no significant difference between the two groups (P> 0.05). Conclusion In the treatment of advanced gastrointestinal cancer, DC-CIK cellular immunotherapy combined with standard chemotherapy can not improve the short-term efficacy of patients with advanced gastrointestinal cancer, but can improve the quality of life and 1-year survival rate of patients with good safety, No obvious side effects.